MDT-AP-1209
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 51.96
- os_event
- false
- age_years
- 8
- sex
- M
- new_clusters
- C3
- umap1_2d
- 5.313502472
- umap2_2d
- 2.632648153
- umap1_3d
- 2.178413216
- umap2_3d
- -3.066041532
- umap3_3d
- -2.637757628
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.410
- INTERFERON_GAMMA_RESPONSE+0.390
- TNFA_SIGNALING_VIA_NFKB+0.380
- IL6_JAK_STAT3_SIGNALING+0.370
- INFLAMMATORY_RESPONSE+0.320
- TGF_BETA_SIGNALING+0.280
- IL2_STAT5_SIGNALING+0.270
- NOTCH_SIGNALING+0.260
- UV_RESPONSE_DN+0.260
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.210
Top 10 suppressed
- E2F_TARGETS-0.440
- MYC_TARGETS_V1-0.420
- G2M_CHECKPOINT-0.380
- OXIDATIVE_PHOSPHORYLATION-0.320
- MYC_TARGETS_V2-0.250
- UNFOLDED_PROTEIN_RESPONSE-0.160
- DNA_REPAIR-0.130
- GLYCOLYSIS-0.130
- PEROXISOME-0.110
- SPERMATOGENESIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CN-5373-01A-01R-1436-07 | — | — | 0.887 |
| 2 | 653522fe-3289-4e1f-9373-c81f923893a3 | — | — | 0.885 |
| 3 | TCGA-A2-A0YD-01A-11R-A109-07 | — | A | 0.884 |
| 4 | SRR8518124 | — | D | 0.880 |
| 5 | TCGA-CV-6943-01A-11R-1915-07 | — | — | 0.878 |
| 6 | MNG416 | — | — | 0.874 |
| 7 | b02dc7a2-3615-4b6c-a3dd-a866d8561d9d | — | — | 0.865 |
| 8 | SRR8613803 | — | D | 0.864 |
| 9 | SRR5088824 | — | — | 0.863 |
| 10 | BS_1RXZ3BP7 | low-grade glioma | — | 0.862 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.410 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.390 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.380 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.370 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.260 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.210 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.210 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.170 | Inavolisib | — uncovered |
| HYPOXIA | 0.170 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.170 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.160 | Temsirolimus | — uncovered |
| ALLOGRAFT_REJECTION | 0.120 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.110 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.110 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.110 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.090 | Temsirolimus | — uncovered |